Health
6.5
FDA mandates GLP-1 labels warn of rare blindness risk NAION
Published 20 h ago3 sourcesEvidence: Reported
SeverityModerateBBC WorldUS
HealthReportedMedium
5.6
FDA Adds Eye Risk Warning to GLP-1 Labels After Review of 126 Trials
The FDA is mandating new warnings on GLP-1 drugs like Ozempic regarding a possible increased risk of a rare eye disease, based on a review of 126 clinical trials involving over 134,000 patients. The data is not fully conclusive, indicating uncertainty about the causal link. This regulatory action could affect prescribing patterns and manufacturer liability, with potential implications for the pharmaceutical sector.
AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works
Score Breakdown
Mosaic Score5.6
Model confidence0.7
Significance0.5
Source credibility0.2
Related signals
8 foundHealth
4.9
FDA warns GLP-1 drugs Ozempic, Mounjaro may raise risk of serious eye condition
Published 1 d ago1 sourceEvidence: Reported
SeverityModeratePoder360Low-rated sourceUS
Health
4.7
FDA flags rare eye-stroke risk in GLP-1 drugs
Published 1 d ago1 sourceEvidence: Reported
SeverityModerateSTAT NewsLow-rated sourceUS
Health
4.8
Harvard study links Novo's Ozempic to increased risk of vision loss
Published 1 d ago1 sourceEvidence: Reported
SeverityModerateEl FinancieroLow-rated sourceUS
Health
5.8
FDA mandates vision-loss warning on weight-loss pens after rare eye disease signal
Published 22 h ago3 sourcesEvidence: Reported
SeverityModerateAssessedDeveloping storyInfoMoneyUS
Health
5.2
FDA Approves Novel Stroke Drug; Warns GLP-1s May Raise Eye Condition Risk
Published 1 d ago3 sourcesEvidence: Reported
SeverityModerateAssessedDeveloping storySTAT NewsLow-rated sourceUS
Health
4.8
FDA flags rare optic nerve damage risk in diabetes/weight drugs after trial review
Published 22 h ago2 sourcesEvidence: Reported
SeverityModerateInfobaeLow-rated sourceUS
Health
6.6
Gene therapy cancer risk confirmed in small case series
Published 2 d ago1 sourceEvidence: Reported
SeverityHighAssessedDeveloping storySTAT NewsLow-rated source